DIRS.INFO The most relevant business & tech news

☆ This AI play is about to pass Warren Buffett’s Berkshire Hathaway in market value
▼ + stars: | 2024-06-20 | by ( Yun Li | ) www.cnbc.com time to read: +3 min

Once-obscure chipmaker Broadcom has enjoyed a record-setting rally that's pushed its market capitalization inches behind Warren Buffett's Berkshire Hathaway conglomerate and its portfolio of household names and economic bellwethers. When Broadcom hit an all-time high earlier this week, its market capitalization briefly surpassed drug maker Eli Lilly's. As of Tuesday's close, Broadcom had a market cap of $839 billion, right behind Eli Lilly's $845 billion and Berkshire's $882 billion. Omaha-based Berkshire is currently No.7 in market value, after a cluster of megacap technology giants. Big AI beneficiary Broadcom, meanwhile, is seeing strong demand from customers in need of high-capacity chips that can power complex AI applications.

Persons: that's, Warren Buffett's, Eli Lilly's, Hock Tan, Steve Sosnick, Tesla, Morgan Stanley Organizations: Broadcom, Warren, Warren Buffett's Berkshire Hathaway, Apple, Berkshire, BNSF Railway, Geico Insurance, U.S ., PetroChina, Bank of America, Interactive Brokers, VMware Locations: Palo Alto , California, Omaha, Berkshire, U.S, Saudi Aramco

☆ How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
▼ + stars: | 2024-06-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Skyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new heights over the last year. But the drugmaker has much more work it wants to do with that hard-won success, outgoing Chief Financial Officer Anat Ashkenazi told CNBC. Ashkenazi took over as CFO at Eli Lilly in 2021 after roughly two decades with the pharmaceutical giant. Her tenure hasn't come without challenges: Eli Lilly and rival Novo Nordisk have both struggled to manufacture enough supply of their treatments to meet unprecedented demand, causing nationwide shortages of those drugs. Eli Lilly does not expect to match the pace of demand this year and maybe not even in 2025, Ashkenazi said at a conference in March.

Persons: Eli Lilly, Anat Ashkenazi, Eli, Zepbound, Ashkenazi, Eli Lilly's Organizations: CNBC, Novo Nordisk

☆ This portfolio chip stock is the second-best AI play behind Nvidia
▼ + stars: | 2024-06-13 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "Behind Nvidia, it's the second-best way to play AI in the chips space," said Jeff Marks, the Club's director of portfolio analysis. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Jerome Powell, Jeff Marks, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Broadcom, Management, Michigan, Club, Novo Nordisk, Bloomberg

☆ Eli Lilly may have developed the greatest drug of all time, says Jim Cramer
▼ + stars: | 2024-06-11 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly may have developed the greatest drug of all time, says Jim Cramer'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.

Persons: Eli Lilly, Jim Cramer, Eli Lilly's

☆ A successful Alzheimer's drug will help Eli Lilly join the $1 trillion club
▼ + stars: | 2024-06-11 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. The billions of dollars in Eli Lilly is investing in manufacturing capacity support the idea that the long-term opportunity is immense. Adding Eli Lilly to the market could help address some of the obstacles that limited Leqembi's sales early on. Eli Lilly, which has spent billions in search of a successful Alzheimer's treatment , had hoped for donanemab to be approved by now. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.

Persons: Eli Lilly, donanemab, Eli Lilly's, Donanemab, Leqembi —, Biogen, —, Jim Cramer's, Ken Langone, Morgan Stanley, Cantor Fitzgerald, Leqembi, Jim Cramer, Jim, Scott Olson Organizations: Food and Drug Administration, FactSet, Novo Nordisk, FDA, GE Healthcare, CNBC, Company, Getty Locations: GLP, Indianapolis , Indiana

☆ Jim Cramer looks at Eli Lilly's outlook as the company's Alzheimer drug goes through FDA
▼ + stars: | 2024-06-11 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJim Cramer looks at Eli Lilly's outlook as the company's Alzheimer drug goes through FDA'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.

Persons: Jim Cramer, Eli Lilly's Organizations: FDA

☆ Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
▼ + stars: | 2024-06-11 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical giant Eli Lilly . Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, he said the company's new Alzheimer's treatment has the potential to further boost business. On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended Eli Lilly's Alzheimer's drug, currently known as donanemab. "I think this advisory committee decision on their Alzheimer's drug does precisely that." Eli Lilly did not immediately respond to request for comment.

Persons: CNBC's Jim Cramer, Eli Lilly, Eli Lilly's, it's, Cramer, they've Organizations: Food and Drug Administration, FDA Locations: U.S, Biogen

☆ Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first time
▼ + stars: | 2024-06-11 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first timeDr. Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the future of Alzheimer's treatments, and more.

Persons: Fillit, Eli Lilly's Alzheimer's, Howard Fillit, Eli Lilly's Organizations: Discovery Foundation, FDA

☆ Eli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared Holz
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared HolzJared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss the FDA's review of Eli Lilly's experimental Alzheimer drug, whether the drug is a game changer, and more.

Persons: Eli, Jared Holz Jared Holz, Eli Lilly's Organizations: Mizuho Securities Locations: Mizuho

☆ FDA advisers say Eli Lilly's Alzheimer's treatment is effective
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly's Alzheimer's treatment is effectiveCNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.

Persons: Eli Lilly's, Angelica Peebles

☆ FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
▼ + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly 's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and its Japanese partner Eisai. In a second vote, advisors unanimously said the benefits of Eli Lilly's donanemab outweigh its risks. It was another blow to Eli Lilly, which initially expected donanameb to win approval at the end of last year.

Persons: Eli Lilly, Eli Lilly's donanemab, Eisai, Eli Lilly's, Sarah Dolan, Dolan, Mark Mintun, donanameb, Leerink, David Risinger, Risinger Organizations: Food and Drug Administration, FDA Locations: Indianapolis , Indiana, U.S, Biogen, Black

☆ FDA advisers say Eli Lilly Alzheimer's treatment is effective
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly Alzheimer's treatment is effectiveDr. Scott Gottlieb, Former FDA Commissioner, joins 'Closing Bell Overtime' to talk news that the FDA has deemed Eli Lilly's Alzheimers treatment as effective.

Persons: Eli Lilly Alzheimer's, Scott Gottlieb, Eli Lilly's Organizations: FDA

☆ Jim Cramer's week ahead: Fed meeting and CPI report
▼ + stars: | 2024-06-07 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Friday guided investors through next week's most market-moving events, highlighting the Federal Reserve's meeting and the latest consumer price index report. Nvidia will implement its 10-for-1 stock split, and Cramer said shares might drop on Monday as buyers take profits. Oracle reports on Tuesday, and Cramer said he's not sure how this enterprise software company will fare. Casey's General Stores will also report that day, and Cramer said business is strong and the stock has been "a total winner." In that vein, the Fed will likely leave rates higher for longer at its Wednesday meeting, Cramer said.

Persons: CNBC's Jim Cramer, Jay Powell, Eli Lilly, Cramer, Eli Lilly's, he's, hasn't, nonfarm, He'll Organizations: Nvidia, Apple, Apple's, Conference, Vision Pro, FDA, Oracle, Casey's, Broadcom, Signet, Adobe Locations: Figma

☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
▼ + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com time to read: +10 min

Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.

Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey

☆ Alphabet taps Eli Lilly's Anat Ashkenazi as new CFO
▼ + stars: | 2024-06-05 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +2 min

Eli Lilly CFO Anat Ashkenazi will become Alphabet's new chief financial officer effective July 31, Google's parent company announced Tuesday, almost a year after Alphabet first announced current CFO Ruth Porat would move to a new role as president and chief investment officer. Ashkenazi has had a 23-year career at Eli Lilly, which in a separate release confirmed her departure. Ashkenazi joined Eli Lilly in 2001 and had been CFO since 2021. She previously served as a CFO for several of the company's global business areas, helping to manage the revenue windfall from Eli Lilly's weight loss and diabetes drugs. Porat had nearly three-decade career as as an investment banker at Morgan Stanley, culminating as its CFO, before joining Google in 2015.

Persons: Eli Lilly, Anat Ashkenazi, Ruth Porat, Ashkenazi, Sundar Pichai, Eli Lilly's, Porat, Morgan Stanley, Philipp Schindler, Prabhakar Raghavan, Thomas Kurian, Susan Wojcicki, Robert Kyncl, Geoffrey Hinton, — CNBC's Jenn Elias, Annika Kim Constantino Organizations: Google, CNBC, YouTube

☆ Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030, Goldman Sachs says
▼ + stars: | 2024-06-02 | by ( George Glover | ) www.businessinsider.com time to read: +1 min

The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementThe market for weight-loss drugs such as Ozempic and Wegovy will keep surging due to new products including Eli Lilly's Zepbound, according to Goldman Sachs. In a research note the bank forecast that the sector will be worth $130 billion by 2030 — $30 billion higher than its previous projection.

Persons: Goldman Sachs, Eli Lilly's Zepbound, —, Wegovy, Eli Lilly, Chris Shibutani Organizations: FDA, pharma, Service, Nordisk, Business Locations: Danish

☆ Here are the portfolio's top 5 performing stocks since April's Monthly Meeting
▼ + stars: | 2024-05-30 | by ( Morgan Chittum | ) www.cnbc.com time to read: +7 min

The latter fact is on display in our list of top-five performing portfolio stocks since the April 24 close through Wednesday's close, the eve of our May meeting. The chipmaker jumped 44.1% since April's Monthly Meeting. 4, Eli Lilly stock jumped 10.8% since our April 24 meeting. A slew of promising AI announcements helped fuel the stock's strong performance since the April meeting. More broadly, Broadcom has been one of the portfolio's biggest beneficiaries of the AI trade.

Persons: Dow, Jim Cramer, we're, Jim, Costco, Eli Lilly's, Eli Lilly, Jim Cramer's, Spencer Platt Organizations: Nasdaq, Dow Jones Industrial, Nvidia, Apple, China Academy of Information, Communications Technology, iPhone, Bank of America, Costco, Costco Wholesale, Walmart, Club, Broadcom, CNBC, Traders, New York Stock Exchange, Getty Locations: Wednesday's, China, U.S, Google's, New York City

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Below $200 a share is the level we'd get interested in buying more Salesforce stock, Jim said. The industrial name will continue to be a beneficiary of the AI trade due to Eaton's booming data center business. Alphabet : If this mega-cap name experiences a move lower, investors should scoop up shares, Jim said. Nvidia : There's not much more to say about Nvidia in light of another blowout earnings report and the strong guidance accompanying it.

Persons: Jim Cramer's, Jim, Apple's, Goldman Sachs, Salesforce, We've, Danaher, he'd, Walt Disney, We're, Estee Lauder, Eaton, Ford, Motors, Mary Dillon's, It's, Linde, Eli Lilly, Mark Zuckerberg's, Morgan Stanley, we're, Stanley Black, we've, Wynn, Jim Cramer, Michael M Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Abbott Labs, Amazon Web Services, Broadcom, Dell, Samsung, Costco Wholesale, Coterra Energy, DuPont De Nemours, DuPont, The, Eaton, Ford, GE Healthcare, Honeywell, Jim, Linde, Microsoft, Nvidia, Palo Alto Networks, Palo Alto, Change, Procter & Gamble, Constellation Brands, Constellation, Modelo, Corona, Federal Reserve, TJX, Marshalls, Wynn Resorts, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: China, Dover, Eaton, U.S, Maxx, HomeGoods, Wells Fargo, Macau, New York City

☆ CNBC Daily Open: Musk's AI start-up raises $6 billion
▼ + stars: | 2024-05-28 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Nvidia's stock rose 2.6% on Friday, contributing to a 15% surge for the week, while the Nasdaq led major indexes with a 1.41% weekly gain. Nvidia CEO's net worth soarsNvidia CEO Jensen Huang's net worth soared to over $90 billion as better-than-expected earnings sent the company's stock soaring to a record high. Last Thursday, the stock rose more than 9% to close at nearly $1,038 per share. Google AI Overview misfiresGoogle's "AI Overview" feature in search is facing criticism for producing incorrect or controversial responses.

Persons: Jensen, Huang, Glass Lewis, Elon Musk, Obama, Eli Lilly, Eli Lilly's, Weizhen Tan Organizations: CNBC, Nasdaq, Dow Jones, Treasury, Nvidia, Investors, Google Locations: Texas, Indiana

☆ Ozempic doesn't make everyone thin. That opens up an opportunity for some stocks
▼ + stars: | 2024-05-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +7 min

Or, in other cases, it can open the door to new options for the treatment of obstructive sleep apnea. Treating obesity and addressing sleep apnea Sleep apnea is a serious sleep disorder that results in interrupted breathing, preventing patients — and even their sleeping partners — from getting restful and restorative sleep. Obstructive sleep apnea, the most common form, occurs when muscles in the throat relax and collapse preventing air flow. Before qualifying for the device, patients usually need to have tried treatment with a CPAP machine and an oral device and been unsuccessful. He downgraded Inspire shares to hold at the beginning of the year due to this uncertainty he was anticipating.

Persons: Eli Lilly's Zepbound, Anthony Petrone, Medical's, Eli Lilly, Tim Herbert, Zepbound, Herbert, FactSet, Petrone, UnitedHealth, Jonathan Block Organizations: Novo Nordisk's, Mizuho Securities, CNBC, Systems, Inspire, American Diabetes Association, Drug Administration, National Institutes of Health, BMI Locations: U.S

In addition to Wegovy and Ozempic, the GLP-1 class includes Eli Lilly's highly popular weight loss drug Zepbound and diabetes treatment Mounjaro. VanGilder signed up nearly four years ago and started taking the weekly diabetes injection Ozempic specifically for weight loss. The big difference between Calibrate and prior weight loss efforts, VanGilder said, is that she doesn't feel like she's dieting. Calibrate is one of the only companies to regularly release reports detailing the results of its weight loss program. The federal Medicare program by law can't cover weight loss drugs unless the prescription is for another approved health benefit, such as diabetes or cardiovascular health.

Persons: Michael Siluk, Gray Beard, She'd, that's, Beard, wouldn't, She's, Ro, Goldman Sachs, Eli Lilly's, it's, Andrew Dudum, There's, Zachariah Reitano, Reitano, Wegovy, WeightWatchers, Gary Foster, Foster, Oprah Winfrey's, Kim Gradwell, Lee Smith, Jennifer VanGilder, she'd, Jenny Craig, VanGilder, I've, Kristin Baier, Rob MacNaughton, Ro's Reitano, we'd, Eli Lilly, Craig Primack, Primack, Hims, Dudum, We're Organizations: — Novo, UCG, Novo Nordisk, CNBC, Teladoc Health, World Health Organization, Food, WeightWatchers Clinic, Ursinus College, Asset Management Locations: Charlotte , North Carolina, U.S, Dudley , North Tyneside, Britain, Collegeville , Pennsylvania, Hims

☆ Eli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earnings
▼ + stars: | 2024-05-24 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Wall Street was bouncing higher Friday after, as Jim Cramer put it, a "really bad day" in the prior session. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Thursday's, Goldman Sachs, Cramer, Eli Lilly, Locker, Mary Dillon, Nike isn't, Jim Cramer's, Jim Organizations: CNBC, Nvidia, Novo Nordisk, Costco, Nike, Jim Cramer's Charitable Locations: America, Indiana

☆ Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
▼ + stars: | 2024-05-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Eli Lilly on Friday said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana, to boost supply of its highly popular weight loss drug Zepbound, diabetes treatment Mounjaro and other medicines. That makes it Eli Lilly's largest manufacturing investment in its nearly 150-year history, the company's CEO David Ricks said in a statement. Eli Lilly expects the Lebanon site to start making medicines toward the end of 2026, and scale up operations through 2028. The plant will specifically increase Eli Lilly's capacity to manufacture the active ingredient in Zepbound and Mounjaro, called tirzepatide.

Persons: Eli Lilly’s, Eli Lilly, Eli Lilly's, David Ricks, Ricks, Anat Ashkenazi, Ashkenazi Organizations: Nexus Pharmaceuticals, Investors Locations: New York City, Lebanon , Indiana, U.S, Lebanon, Indiana, Europe, North Carolina, Ireland, Germany

☆ Cramer's Lightning Round: Sigma Lithium is 'too dicey'
▼ + stars: | 2024-05-23 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Arista Networks' year-to-date stock performance. Stock Chart Icon Stock chart icon Sigma Lithium's year-to-date stock performance. Stock Chart Icon Stock chart icon Trump Media & Technology Group's year-to-date stock performance. Stock Chart Icon Stock chart icon Eli Lilly's year-to-date stock performance. Stock Chart Icon Stock chart icon Sony Group's year-to-date stock performance.

Persons: Jayshree, Eli Lilly's, Eli Lilly, it's, Jim Cramer's Organizations: Arista Networks, Arista, Sigma, Trump Media & Technology, Sony

☆ This overlooked obesity-drug stock has 80% upside, JPMorgan says
▼ + stars: | 2024-05-21 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. "Meaningful upside from even a small piece of unprecedentedly large GLP-1 market," JPMorgan said. AdvertisementStructure Therapeutics is developing the drug candidate dubbed "1290," which is a "pure-play option" for the GLP-1 weight loss market, according to JPMorgan. JPMorgan said early results suggest the drug candidate offers "on par" weight loss results for patients with "no major concerns on safety." Advertisement"We think GPCR's market share in the oral market can approach 5% over time in an unprecedentedly large market.

Persons: —, Eli Lilly, Eli, orforglipron, Eli Lilly's Organizations: Therapeutics, JPMorgan, Service, Novo Nordisk, GLPP, Nasdaq

Search resuls for: "Lilly's"

25 mentions found